Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
A reproducibility study in pulmonary adenocarcinomas supports a revised classification
Reducing stigma for lung cancer and other smoking-related respiratory diseases